卡培他滨联合适形调强放射治疗老年中晚期食管癌的疗效

Efficacy of capecitabine combined with conformal intensity-modulated radiation therapy in elderly patients with moderately advanced esophageal cancer

目的研究卡培他滨联合适形调强放射治疗老年中晚期食管癌的疗效和安全性。方法选取2017年5月至2018年5月兴化市第三人民医院收治的80例老年中晚期食管癌患者为研究对象,依据随机数字表法将其分为对照组和试验组,每组40例。适形调强放射治疗应用于对照组患者;在其基础上,试验组患者通过口服卡培他滨进行联合治疗。比较两组治疗后的临床疗效、局部控制率、生存率与复发率、治疗前后的免疫功能及治疗期间不良反应发生情况。结果治疗后,试验组临床总有效率80.00%,明显高于对照组的57.50%(P<0.05);治疗后,两组血清免疫球蛋白A(IgA)、免疫球蛋白G(IgG)与免疫球蛋白M(IgM)均高于治疗前,且试验组高于对照组(P<0.05);试验组患者局部控制率与1年生存率均高于对照组,复发率低于对照组(P<0.05);治疗期间,两组不良反应评分比较,差异无统计学意义(P>0.05)。结论卡培他滨联合适形调强放射治疗老年中晚期食管癌疗效显著,可有效缓解患者的临床症状,增强其免疫功能,提高肿瘤局部控制率与生存率,且可减少不良反应,安全性高。

Objective To investigate the efficacy and safety of capecitabine combined with conformal intensitymodulated radiation therapy for elderly patients with moderately advanced esophageal cancer.Methods A total of 80 elderly patients with advanced or middle-aged esophageal cancer who were admitted to the Xinghua Third People's Hospital from May 2017 to may 2018 were selected as the study subjects and divided into control and test groups according to the random number table method,with 40 cases in each group.Conformal intensity-modulated radiation mtherapy was applied to patients in the control group;On its basis,patients in the test group were treated orally by combination with capecitabine.The clinical outcomes,local control,survival and recurrence,immune function before and after treatment,and occurrence of adverse effects during treatment were compared between the two groups.Results After treatment,the clinical overall response rate of the test group was 80.00%,which was significantly higher than that of the control group by 57.50%(P<0.05).After treatment,the serum levels of immunoglobulin A(IGA),immunoglobulin G(IgG),and immunoglobulin M(IgM)were higher in both groups than before treatment,and all the level of immune function in the test group were higher than the control group(P<0.05).The rates of local control and 1-year survival in the test group were higher than those in the control group,and the rates of recurrence were lower than those in the control group(P<0.05);During treatment,there was no significant difference in adverse effect scores between the two groups(P>0.05).Conclusions Capecitabine combined with conformal intensitymodulated radiation therapy in elderly patients with moderately advanced esophageal cancer is highly effective in relieving the clinical symptoms of patients,enhancing their immune function,and improving the local control rate and survival rate of the tumor,as well as reducing adverse effects and have a high safety profile.